Erythropoietin resistance contributes to anaemia in chronic heart failure and relates to aberrant JAK-STAT signal transduction

Darlington O. Okonko, Stephen B. Marley, Stefan D. Anker, Philip A. Poole-Wilson, Myrtle Y. Gordon

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Chronic heart failure (CHF) patients are frequently anaemic despite elevated endogenous erythropoietin (Epo) levels. We tested the hypothesis that this might be due to Epo resistance and investigated whether any defects apparent were due to Epo receptor (EpoR) downregulation and/or impaired Epo-induced signal transduction. Methods: We studied 28 CHF patients (age 64 ± 10 yrs, LVEF 29 ± 9%, 89% male) and 12 healthy controls (65 ± 11 yrs, 75% male). Circulating erythroid progenitors (BFU-E) were cultured with 0, 1, 3 and 9 U/mL Epo. Circulating erythroblast surface EpoR and intracellular phosphorylated Signal Transducer and Activator of Transcription (phosphoSTAT)-5 expression were determined by flow cytometry. Results: Whilst BFU-E from control and non-anaemic subjects required only 3 U/mL Epo to significantly increase their numbers from baseline (1 U/mL), those from anaemic patients required 9 U/mL Epo. Lower Epo sensitivities related to higher interleukin-6 (r = - 0.41, P = 0.01) and soluble tumour necrosis factor receptor 2 (r = - 0.38, P = 0.02) levels. EpoR-positive cells were more abundant in anaemic patients (P <0.001). Although erythroblasts from anaemic patients exhibited higher baseline EpoR and phosphoSTAT5 expression (all P <0.05), Epo stimulation triggered significant increases in phosphoSTAT5 levels only in erythroblasts from control subjects and not in those from anaemic patients. Conclusion: The responsiveness of erythroid cells to Epo is diminished in anaemic CHF patients. This is not due to EpoR downregulation but relates to a profound blunting of Epo-induced JAK-STAT signalling. Whilst residual Epo sensitivity can be exploited clinically with erythropoietic agents, targeting the mechanisms underlying Epo resistance in CHF may provide greater efficacy.

Original languageEnglish
Pages (from-to)359-364
Number of pages6
JournalInternational Journal of Cardiology
Volume164
Issue number3
DOIs
Publication statusPublished - Apr 15 2013

Fingerprint

Erythropoietin
Anemia
Signal Transduction
Heart Failure
Erythroblasts
Erythroid Precursor Cells
Down-Regulation
STAT5 Transcription Factor
Receptors, Tumor Necrosis Factor, Type II
Erythropoietin Receptors
Erythroid Cells
Interleukin-6
Flow Cytometry

Keywords

  • Anaemia
  • Erythropoietin resistance
  • Heart failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Erythropoietin resistance contributes to anaemia in chronic heart failure and relates to aberrant JAK-STAT signal transduction. / Okonko, Darlington O.; Marley, Stephen B.; Anker, Stefan D.; Poole-Wilson, Philip A.; Gordon, Myrtle Y.

In: International Journal of Cardiology, Vol. 164, No. 3, 15.04.2013, p. 359-364.

Research output: Contribution to journalArticle

Okonko, Darlington O. ; Marley, Stephen B. ; Anker, Stefan D. ; Poole-Wilson, Philip A. ; Gordon, Myrtle Y. / Erythropoietin resistance contributes to anaemia in chronic heart failure and relates to aberrant JAK-STAT signal transduction. In: International Journal of Cardiology. 2013 ; Vol. 164, No. 3. pp. 359-364.
@article{0e18a41226db4f5da6538107752cbef4,
title = "Erythropoietin resistance contributes to anaemia in chronic heart failure and relates to aberrant JAK-STAT signal transduction",
abstract = "Background: Chronic heart failure (CHF) patients are frequently anaemic despite elevated endogenous erythropoietin (Epo) levels. We tested the hypothesis that this might be due to Epo resistance and investigated whether any defects apparent were due to Epo receptor (EpoR) downregulation and/or impaired Epo-induced signal transduction. Methods: We studied 28 CHF patients (age 64 ± 10 yrs, LVEF 29 ± 9{\%}, 89{\%} male) and 12 healthy controls (65 ± 11 yrs, 75{\%} male). Circulating erythroid progenitors (BFU-E) were cultured with 0, 1, 3 and 9 U/mL Epo. Circulating erythroblast surface EpoR and intracellular phosphorylated Signal Transducer and Activator of Transcription (phosphoSTAT)-5 expression were determined by flow cytometry. Results: Whilst BFU-E from control and non-anaemic subjects required only 3 U/mL Epo to significantly increase their numbers from baseline (1 U/mL), those from anaemic patients required 9 U/mL Epo. Lower Epo sensitivities related to higher interleukin-6 (r = - 0.41, P = 0.01) and soluble tumour necrosis factor receptor 2 (r = - 0.38, P = 0.02) levels. EpoR-positive cells were more abundant in anaemic patients (P <0.001). Although erythroblasts from anaemic patients exhibited higher baseline EpoR and phosphoSTAT5 expression (all P <0.05), Epo stimulation triggered significant increases in phosphoSTAT5 levels only in erythroblasts from control subjects and not in those from anaemic patients. Conclusion: The responsiveness of erythroid cells to Epo is diminished in anaemic CHF patients. This is not due to EpoR downregulation but relates to a profound blunting of Epo-induced JAK-STAT signalling. Whilst residual Epo sensitivity can be exploited clinically with erythropoietic agents, targeting the mechanisms underlying Epo resistance in CHF may provide greater efficacy.",
keywords = "Anaemia, Erythropoietin resistance, Heart failure",
author = "Okonko, {Darlington O.} and Marley, {Stephen B.} and Anker, {Stefan D.} and Poole-Wilson, {Philip A.} and Gordon, {Myrtle Y.}",
year = "2013",
month = "4",
day = "15",
doi = "10.1016/j.ijcard.2011.07.045",
language = "English",
volume = "164",
pages = "359--364",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Erythropoietin resistance contributes to anaemia in chronic heart failure and relates to aberrant JAK-STAT signal transduction

AU - Okonko, Darlington O.

AU - Marley, Stephen B.

AU - Anker, Stefan D.

AU - Poole-Wilson, Philip A.

AU - Gordon, Myrtle Y.

PY - 2013/4/15

Y1 - 2013/4/15

N2 - Background: Chronic heart failure (CHF) patients are frequently anaemic despite elevated endogenous erythropoietin (Epo) levels. We tested the hypothesis that this might be due to Epo resistance and investigated whether any defects apparent were due to Epo receptor (EpoR) downregulation and/or impaired Epo-induced signal transduction. Methods: We studied 28 CHF patients (age 64 ± 10 yrs, LVEF 29 ± 9%, 89% male) and 12 healthy controls (65 ± 11 yrs, 75% male). Circulating erythroid progenitors (BFU-E) were cultured with 0, 1, 3 and 9 U/mL Epo. Circulating erythroblast surface EpoR and intracellular phosphorylated Signal Transducer and Activator of Transcription (phosphoSTAT)-5 expression were determined by flow cytometry. Results: Whilst BFU-E from control and non-anaemic subjects required only 3 U/mL Epo to significantly increase their numbers from baseline (1 U/mL), those from anaemic patients required 9 U/mL Epo. Lower Epo sensitivities related to higher interleukin-6 (r = - 0.41, P = 0.01) and soluble tumour necrosis factor receptor 2 (r = - 0.38, P = 0.02) levels. EpoR-positive cells were more abundant in anaemic patients (P <0.001). Although erythroblasts from anaemic patients exhibited higher baseline EpoR and phosphoSTAT5 expression (all P <0.05), Epo stimulation triggered significant increases in phosphoSTAT5 levels only in erythroblasts from control subjects and not in those from anaemic patients. Conclusion: The responsiveness of erythroid cells to Epo is diminished in anaemic CHF patients. This is not due to EpoR downregulation but relates to a profound blunting of Epo-induced JAK-STAT signalling. Whilst residual Epo sensitivity can be exploited clinically with erythropoietic agents, targeting the mechanisms underlying Epo resistance in CHF may provide greater efficacy.

AB - Background: Chronic heart failure (CHF) patients are frequently anaemic despite elevated endogenous erythropoietin (Epo) levels. We tested the hypothesis that this might be due to Epo resistance and investigated whether any defects apparent were due to Epo receptor (EpoR) downregulation and/or impaired Epo-induced signal transduction. Methods: We studied 28 CHF patients (age 64 ± 10 yrs, LVEF 29 ± 9%, 89% male) and 12 healthy controls (65 ± 11 yrs, 75% male). Circulating erythroid progenitors (BFU-E) were cultured with 0, 1, 3 and 9 U/mL Epo. Circulating erythroblast surface EpoR and intracellular phosphorylated Signal Transducer and Activator of Transcription (phosphoSTAT)-5 expression were determined by flow cytometry. Results: Whilst BFU-E from control and non-anaemic subjects required only 3 U/mL Epo to significantly increase their numbers from baseline (1 U/mL), those from anaemic patients required 9 U/mL Epo. Lower Epo sensitivities related to higher interleukin-6 (r = - 0.41, P = 0.01) and soluble tumour necrosis factor receptor 2 (r = - 0.38, P = 0.02) levels. EpoR-positive cells were more abundant in anaemic patients (P <0.001). Although erythroblasts from anaemic patients exhibited higher baseline EpoR and phosphoSTAT5 expression (all P <0.05), Epo stimulation triggered significant increases in phosphoSTAT5 levels only in erythroblasts from control subjects and not in those from anaemic patients. Conclusion: The responsiveness of erythroid cells to Epo is diminished in anaemic CHF patients. This is not due to EpoR downregulation but relates to a profound blunting of Epo-induced JAK-STAT signalling. Whilst residual Epo sensitivity can be exploited clinically with erythropoietic agents, targeting the mechanisms underlying Epo resistance in CHF may provide greater efficacy.

KW - Anaemia

KW - Erythropoietin resistance

KW - Heart failure

UR - http://www.scopus.com/inward/record.url?scp=84884213329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884213329&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2011.07.045

DO - 10.1016/j.ijcard.2011.07.045

M3 - Article

VL - 164

SP - 359

EP - 364

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 3

ER -